2023
The natural history of aortic root aneurysms
Ziganshin B, Kargin N, Zafar M, Elefteriades J. The natural history of aortic root aneurysms. Annals Of Cardiothoracic Surgery 2023, 12: 21324-21224. PMID: 37304695, PMCID: PMC10248916, DOI: 10.21037/acs-2023-avs1-20.Peer-Reviewed Original Research
2022
Bovine Aortic Arch: A Result of Chance or Mandate of Inheritance?
Shang M, Vinholo TF, Buntin J, Zafar MA, Ziganshin BA, Elefteriades JA. Bovine Aortic Arch: A Result of Chance or Mandate of Inheritance? The American Journal Of Cardiology 2022, 172: 115-120. PMID: 35321803, PMCID: PMC9978865, DOI: 10.1016/j.amjcard.2022.02.030.Peer-Reviewed Original ResearchConceptsBovine archThoracic aortic aneurysmAortic aneurysmThoracic aortic aneurysm diseaseAortic arch configurationAortic aneurysm diseaseSecond-degree relativesInstitutional databaseAneurysm diseaseChest imagingPatientsAneurysmsAvailable scansGenetic mutationsArch resultsArchArch configurationFamily membersSample populationProbandsScansMagnetic resonanceResult of chancePrevious studiesChest
2021
Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms
Weininger G, Chan SM, Zafar M, Ziganshin BA, Elefteriades JA. Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms. Expert Review Of Cardiovascular Therapy 2021, 19: 619-631. PMID: 34102944, DOI: 10.1080/14779072.2021.1940958.Peer-Reviewed Original ResearchConceptsAortic aneurysmAbdominal aortic aneurysmß-blockersAngiotensin II receptor blockersAngiotensin-converting enzyme inhibitorAnti-platelet medicationDifferent pharmacologic therapiesII receptor blockersAortic aneurysm patientsThoracic aortic aneurysmRisk reductionAortic aneurysm growthPharmacologic managementReceptor blockersPharmacologic therapyMedical therapySurgical interventionAneurysm patientsMiscellaneous drugsAneurysm diseasePharmacological strategiesSyndrome patientsMarfan syndromeEnzyme inhibitorsAneurysmsIs Aortic Z-score an Appropriate Index of Beneficial Drug Effect in Clinical Trials in Aortic Aneurysm Disease?
Elkinany S, Weismann C, Curtis A, Smith T, Zafar MA, Breen T, Li Y, Tranquilli M, Rizzo JA, Mukherjee SK, Ziganshin BA, Elefteriades JA. Is Aortic Z-score an Appropriate Index of Beneficial Drug Effect in Clinical Trials in Aortic Aneurysm Disease? The American Journal Of Cardiology 2021, 143: 145-153. PMID: 33352210, DOI: 10.1016/j.amjcard.2020.12.025.Peer-Reviewed Original ResearchConceptsBody mass indexAortic Z-scoresZ-score decreaseBeneficial drug effectsZ-scoreMarfan patientsClinical trialsAneurysm diseaseDrug effectsChild's ageEcho examAortic dilation rateDecreased Z-scoreConnective tissue diseaseBody surface areaEffects of medicationAortic aneurysm diseaseClinical drug trialsMass indexTissue diseaseAortic diseaseAneurysmal pathologyDrug trialsInvestigational drugsSpontaneous decrease
2017
Medical management of aortic disease in Marfan syndrome.
Bin Mahmood SU, Velasquez CA, Zafar MA, Saeyeldin AA, Brownstein AJ, Ziganshin BA, Elefteriades JA, Mukherjee SK. Medical management of aortic disease in Marfan syndrome. Annals Of Cardiothoracic Surgery 2017, 6: 654-661. PMID: 29270377, PMCID: PMC5721117, DOI: 10.21037/acs.2017.11.09.Peer-Reviewed Original ResearchAngiotensin receptor blockersMedical managementMarfan syndromeMFS patientsThoracic aortic aneurysm diseaseDifferent medical regimensStandard of careAortic aneurysm diseaseNumerous pathophysiological effectsAortic dilatationReceptor blockersAortic diseaseMedical regimensCurrent guidelinesAneurysm diseaseCardiovascular organsΒ-blockersCurrent evidencePathophysiological effectsHereditary disorderPatientsSyndromeDiseaseRegimensManagement